Your session is about to expire
← Back to Search
Venetoclax + Azacitidine for Myelodysplastic Syndrome
Study Summary
This trial is testing the combination of venetoclax and azacitidine to see if it is effective and has manageable side effects in treating patients with high-risk myelodysplastic syndrome.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 389 Patients • NCT02005471Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My MDS is classified as low or intermediate-1 risk.I have cognitive impairment.I have previously received BCL2 inhibitor therapy.I am not pregnant and if I can have children, I agree to use birth control during and 3 months after the study.I have high-risk MDS or MDS that didn't respond to previous treatment.I am a male and will use birth control during and for 3 months after the study.
- Group 1: Treatment (venetoclax, azacitidine)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this research currently enrolling participants?
"As per clinicaltrials.gov, this research project is presently recruiting participants. It was first posted on October 1st 2019 and last modified on June 8th 2022."
In what other capacities has Venetoclax been examined?
"At present, 340 Venetoclax trials are active with 54 in Phase 3. Toronto is one of the prime locations for these studies; however, there exist 11,189 clinical trial sites that conduct research on this medication."
How many individuals are currently participating in this trial's proceedings?
"Absolutely. The clinicaltrials.gov website attests to the fact that this trial is currently recruiting individuals, as it was initially posted on October 1st 2019 and recently updated on June 8th 2022. 116 patients are needed from one particular medical site for successful completion of the experiment."
To what maladies is Venetoclax typically prescribed as a remedy?
"Venetoclax is regularly used for induction chemotherapy, yet can also be beneficial in alleviating the symptoms associated with refractory anemias, leukemia, myelocytic and acute multilineage dysplasia."
Share this study with friends
Copy Link
Messenger